Voriconazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Voriconazole
- Molecular weight
- 349.32
- Structure (SMILES)
- C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
- vfend
- Vfend
- voriconazole
- Voriconazole
- voriconazole accord
- Voriconazole accord
- Voriconazole hikma (previously voriconazole hospira)
- voriconazole hikma previously voriconazole hospira
- (.ALPHA.R,.BETA.S)-A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-4-PYRIMIDINEETHANOL
- 4 pyrimidineethanol a 2 4 difluorophenyl 5 fluoro beta methyl alpha 1h 1 2 4 triazol 1 ylmethyl alpha r beta s
- 4-PYRIMIDINEETHANOL, A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-
- alpha r beta s a 2 4 difluorophenyl 5 fluoro beta methyl alpha 1h 1 2 4 triazol 1 ylmethyl 4 pyrimidineethanol
- anidulafungin and voriconazole
- Antifungal drug. VORICONAZOL. (VFEND®)
- no voriconazole (Vfend)
- nsc 759888
- NSC-759888
- oral voriconazole
- uk 109 496
- uk 109496
- UK-109,496
- UK-109496
- Vaway FC Tablets 200mg (Voriconazole)
- VFEND
- Vfend (voriconazole) intravenous infusion
- Vfend (voriconazole) tablet
- VFEND FC Tablets 200mg (Voriconazole)
- Vfend®(Voriconazole) IV 200mg
- Vorico Injection 200mg(Voriconazole)
- voriconazol
- Voriconazol
- voriconazole
- Voriconazole
And 34 more, listed on the interactive page.
- ATC classification codes
- J02AC03
Sources for recorded values
- CAS registry numbers
- 137234-62-9
- ChEMBL ID
- CHEMBL638
- InChIKey
- BCEHBSKCWLPMDN-MGPLVRAMSA-N
- PubChem compound IDs
- 71616
- RxNorm IDs (RxCUI)
- 121243
- FDA ingredient codes (UNII)
- JFU09I87TR
- Applicant
- PF PRISM CV
- Approval date
- 24 May 2002
- Application number
- NDA021266
- Status
- Authorised
- Status date
- 19 Mar 2002
- Authorisation date
- 19 Mar 2002
- Approved indications
- Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis; treatment of in candidaemianon-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Vfend should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
- Product number
- EMEA/H/C/000387
- Authorisation holder
- Pfizer Europe MA EEIG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 2
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Aspergillosis
- Candidiasis
- Mycoses
European medicines record
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Drug name stem
- -conazole
Administration routes
- Oral
- Parenteral
Mechanisms of action
- Mechanism
- Cytochrome P450 51 inhibitor
- Action type
- Inhibitor
- Target
- Lanosterol 14-alpha demethylase
- Protein identifier
- P10613
Open Targets mechanisms
- Mechanism
- Cytochrome P450 51 inhibitor
- Action type
- Inhibitor
- Target
- Lanosterol 14-alpha demethylase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ERG11
- Protein identifier
- P10613
- Organism
- Candida albicans (strain SC5314 / ATCC MYA-2876)
- Condition
- Bacterial Infections and Mycoses
- Highest recorded phase
- 4
- Subject identifier
- D001423
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Leishmaniasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005044
- Subject identifier
- D007896
- Condition
- Aspergillosis, Allergic Bronchopulmonary
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007140
- Subject identifier
- D001229
- Condition
- Aspergillosis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007157
- Subject identifier
- D001228
- Condition
- Neuroaspergillosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007393
- Subject identifier
- D020953
- Condition
- Keratitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0009449
- Subject identifier
- D007634
- Condition
- Candidemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001282
- Subject identifier
- D058387
- Condition
- Candidiasis, Invasive
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001283
- Subject identifier
- D058365
- Condition
- Fusariosis
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001795
- Subject identifier
- D060585
- Condition
- Neutropenia
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001475
- Subject identifier
- D009503
- Condition
- Candidiasis
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002026
- Subject identifier
- D002177
- Condition
- Mycoses
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002041
- Subject identifier
- D009181
- Condition
- Asthma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0013730
- Subject identifier
- D006086
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001642
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004251
- Condition identifier
- EFO_0005044
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007140
- Condition identifier
- EFO_0007157
- Condition identifier
- EFO_0009260
- Condition identifier
- EFO_1001282
- Condition identifier
- EFO_1001282
- Highest recorded phase
- 4
- Condition identifier
- EFO_1001283
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001795
- Condition identifier
- EFO_1002048
- Condition identifier
- HP_0001945
- Highest recorded phase
- 3
- Condition identifier
- HP_0002105
- Highest recorded phase
- 2
- Condition identifier
- HP_0002863
- Condition identifier
- MONDO_0000256
- Condition identifier
- MONDO_0000256
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000266
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001475
- Condition identifier
- MONDO_0001475
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002026
And 28 more, listed on the interactive page.
- Event
- actinic keratosis
- Reports
- 157
- Reporting signal score
- 551.287
- Event
- aspergillosis
- Reports
- 32
- Reporting signal score
- 101.185
- Event
- aspergillus infection
- Reports
- 162
- Reporting signal score
- 521.116
- Event
- basal cell carcinoma
- Reports
- 76
- Reporting signal score
- 93.0774
- Event
- bowen's disease
- Reports
- 71
- Reporting signal score
- 238.172
- Event
- bronchopulmonary aspergillosis
- Reports
- 193
- Reporting signal score
- 614.986
- Event
- cerebral aspergillosis
- Reports
- 35
- Reporting signal score
- 141.069
- Event
- cholestasis
- Reports
- 164
- Reporting signal score
- 265.062
- Event
- choroiditis
- Reports
- 39
- Reporting signal score
- 153.41
- Event
- condition aggravated
- Reports
- 284
- Reporting signal score
- 93.6242
- Event
- dilatation intrahepatic duct acquired
- Reports
- 33
- Reporting signal score
- 140.643
- Event
- drug interaction
- Reports
- 660
- Reporting signal score
- 740.915
- Event
- drug level below therapeutic
- Reports
- 79
- Reporting signal score
- 178.983
- Event
- drug resistance
- Reports
- 118
- Reporting signal score
- 145.932
- Event
- drug-induced liver injury
- Reports
- 93
- Reporting signal score
- 86.757
- Event
- electrocardiogram qt prolonged
- Reports
- 113
- Reporting signal score
- 90.351
- Event
- endophthalmitis
- Reports
- 63
- Reporting signal score
- 120.442
- Event
- fatigue
- Reports
- 47
- Reporting signal score
- 137.824
- Event
- fluoride increased
- Reports
- 37
- Reporting signal score
- 202.747
- Event
- fluorosis
- Reports
- 22
- Reporting signal score
- 114.554
- Event
- fungal infection
- Reports
- 89
- Reporting signal score
- 102.603
- Event
- graft versus host disease
- Reports
- 54
- Reporting signal score
- 104.715
- Event
- hallucination
- Reports
- 277
- Reporting signal score
- 377.318
- Event
- hallucination, visual
- Reports
- 210
- Reporting signal score
- 436.24
- Event
- hepatic function abnormal
- Reports
- 129
- Reporting signal score
- 131.754
And 18 more, listed on the interactive page.
- NCT00001646
- NCT00001810
- NCT00003031
- NCT00159822
- NCT00412893
- NCT00423163
- NCT00531479
- NCT00620074
- NCT00836875
- NCT01080651
- NCT01188759
- NCT01207128
- NCT01383993
- NCT01782131
- NCT01887457
- NCT02180165
- NCT03327727
- NCT03672292
- NCT04824417
- NCT00001757
- NCT00001940
- NCT00015665
- NCT00136968
- NCT00143312
- NCT00150345
And 32 more, listed on the interactive page.
- Dose
- 6 mg/kg
- Route
- Intravenous
- How often
- Every 12 hours for the first 24 hours, then every 12 hours afterwards
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 76.72
- Calculated partition coefficient (ALogP)
- 2.18
- Calculated partition coefficient (XLogP)
- 1.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 25
- Molecular formula
- C16H14F3N5O
- Monoisotopic mass
- 349.11504457
- Natural product
- No
- 0049-3160
- 0049-3180
- 0049-3190
- 0049-4190
- 0121-1091
- 0378-1626
- 0378-1640
- 0781-3416
- 0781-5667
- 0781-5668
- 0904-6596
- 0904-7024
- 14335-730
- 16714-198
- 16714-199
- 27241-062
- 27241-063
- 31722-224
- 31722-266
- 40032-038
- 43386-038
- 43386-088
- 43386-089
- 43547-377
- 43547-378
And 32 more, listed on the interactive page.
- Recorded assays
- 4,623
- Active assays
- 114
- Confirmatory
- Screening
- Antifungal Agents
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
These details could not be displayed.
Related records
Trials (527)
- 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis
- 5% Topical Ibuprofen (IBU) for Ankle Sprain
- A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens
- A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
- A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.
- A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
- A New Hormone Replacement Paradigm: Physiologic Restoration Study
- A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults
- A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream
- A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
- A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails
- A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
- A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
- A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
- A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections
- A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
- A Randomized Controlled Trial of Vitamin D Supplementation on Salivary Biomarkers and Cariogenic Oral Microbiome
- A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
Approved for (5)
- Aspergillosis
- Candidemia
- Candidiasis
- Fungal infectious disease
- Fusariosis
In development for (15)
- Acute myeloid leukemia Phase 3
- Allergic bronchopulmonary aspergillosis Phase 2
- Asthma Phase 1
- B-cell chronic lymphocytic leukemia Phase 1
- Cancer Phase 1
- Candidiasis, invasive Phase 3
- Graft versus host disease Phase 1
- HIV infectious disease Phase 1
- Keratitis Early phase 1
- Leishmaniasis Phase 3
- Leukemia Phase 3
- Lymphoid neoplasm Phase 1
- Myelodysplastic syndrome Phase 2
- Neuroaspergillosis Phase 3
- Neutropenia Phase 1
Other linked conditions (3)
- Breast cancer
- Kidney failure
- Systemic mycosis